37178-28-2

Usage

General Description

1-(benzyloxy)-3-(3,4-dihydroxyphenyl)-1-oxopropan-2-aminium chloride is a chemical compound that contains a positively charged amino group and a chloride ion. It is derived from benzyloxy and 3,4-dihydroxyphenyl, and has a one-oxo-propan-2-aminium group. 1-(benzyloxy)-3-(3,4-dihydroxyphenyl)-1-oxopropan-2-aminium chloride may have potential applications in pharmaceuticals, as it contains a benzyl group, hydroxyphenyl group, and an oxo group, which are common functional groups found in many bioactive compounds. The presence of the chloride ion also gives the compound potential applications in chemical reactions and synthesis. Overall, 1-(benzyloxy)-3-(3,4-dihydroxyphenyl)-1-oxopropan-2-aminium chloride has the potential to be used in various chemical and pharmaceutical applications due to its structural features.

Upstream product

• 59-92-7 levodopa 
• 100-51-6 benzyl alcohol 

Downstream Products

• 113934-60-4 6-Hydroxy-5-oxo-3,5-dihydro-2H-indole-2-carboxylic acid benzyl ester 
• 113934-61-5 3,4-dihydroxyindole-2-carboxylic acid benzyl ester 
• 1454906-81-0 C₃₁H₃₆N₂O₇ 
• 946089-61-8 C₂₅H₃₂N₂O₇ 
• 946089-62-9 C₂₀H₂₄N₂O₅*ClH 
• 1454906-93-4 C₂₄H₃₀N₂O₇ 
• 946089-77-6 C₁₉H₂₂N₂O₅*ClH 
• 946089-70-9 C₁₇H₂₂N₂O₇*ClH 
• 946089-66-3 C₁₃H₁₈N₂O₅*ClH 

Relevant academic research and scientific papers

Synthesis and polymerization studies of organic-soluble eumelanins

The isolation, structure determination and chemical characterization of eumelanins has been plagued by their very low solubility in organic solvents. To gain insights into the structure and reactivity of these unusual and important biologic macromolecules

Design, synthesis and biological evaluation of peptide derivatives of l-dopa as anti-parkinsonian agents

A series of dipeptide derivatives of l-dopa were synthesized and investigated for their pharmacological activity using the unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rat as an experimental model of Parkinson's disease. Among them, (S)-isopropyl 2-(2-amino-2-methylpropanamido)-3-(3,4- dihydroxyphenyl)propanoate (4g) was found to be the most active compound, with 106% AUC activity and 149% peak activity of l-dopa after oral administration.

NON-NATURAL AMINO ACID DERIVATIVES

Compounds of formula (I) have activity in alleviating the effects of impaired dopaminergic signaling, for example in the treatment of Parkinsons Disease; wherein: R1 is a carboxyl, carboxyl ester, or carboxamide group; R2 and R3

Effervescent enteric coated L-dopa formulation and method of using the same

Therapeutic levels of L-DOPA are achieved by orally administering a pharmaceutical effervescent-enteric coated tablet comprising: A. a member selected from the group consisting of L-DOPA or a derivative thereof capable of enzymatically cleaving and reverting to L-DOPA in vivo, B. a non-toxic pharmaceutically acceptable inert diluent, C. a non-toxic pharmaceutically acceptable carbon dioxide releasing agent, D. a non-toxic pharmaceutically acceptable effervescing agent, and E. a non-toxic pharmaceutically acceptable enteric coating. This composition is extremely useful in the treatment of Parkinsonism. When administered to warm-blooded animals (e.g., humans), superior therapeutic blood levels of L-DOPA are observed over that normally observed with conventional enteric coated formulations.

Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease

There is provided, novel, transient pro-drug forms of L-DOPA (3,4-dihydroxy-L-phenylalanine), having the formula: SPC1 Wherein R represents a member selected from the group consisting of a hydrogen atom, a --COCH3 group, a --COC2 Hs

Novel, transient pro-drug forms of L-DOPA

There is provided, novel, transient pro-drug forms of L-DOPA (3,4-dihydroxy-L-phenylalanine), having the formula: STR1 wherein n represents an integer of from 2 to 50 with respect to formula (V-A), and wherein n represents an integer of from 1 to 50 with respect to formula (V-B); R represents a hydrogen atom, an acyl group, STR2 --CO-pyridyl, or --CO--R3, wherein R3 is the residue of any N,N-C1 -C2 dialkylamino acid or a C4 -C6 cycloalkylamino acid; R1 represents --OH, --O-lower alkyl, --O-benzyl, or a naturally occurring protein amino acid; and R2 represents STR3 --CO-pyridyl, a naturally occurring protein amino acid, 3',4'-L-diacyloxy phenylalanine, or --CO-R3. These compounds are all useful in the treatment of Parkinson's Disease.